These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 22678151)

  • 21. High Degree of Desensitization After 1 Year of Early-Life Peanut Oral Immunotherapy: Small Children Oral Immunotherapy (SmaChO) Randomized Controlled Trial.
    Uhl C; Klevebro S; Sverremark-Ekström E; Tedner SG; Brandström J; Papageorgiou C; Melén E; Konradsen JR; Nilsson C; Asarnoj A
    J Allergy Clin Immunol Pract; 2024 May; 12(5):1297-1305. PubMed ID: 38428524
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Modified peanut oral immunotherapy protocol safely and effectively induces desensitization.
    Bird JA; Feldman M; Arneson A; Dougherty I; Brown LS; Burk CM; Kulis M; Burks W; Gill M
    J Allergy Clin Immunol Pract; 2015; 3(3):433-5.e1-3. PubMed ID: 25609341
    [No Abstract]   [Full Text] [Related]  

  • 23. AR101 Oral Immunotherapy for Peanut Allergy.
    ; Vickery BP; Vereda A; Casale TB; Beyer K; du Toit G; Hourihane JO; Jones SM; Shreffler WG; Marcantonio A; Zawadzki R; Sher L; Carr WW; Fineman S; Greos L; Rachid R; Ibáñez MD; Tilles S; Assa’ad AH; Nilsson C; Rupp N; Welch MJ; Sussman G; Chinthrajah S; Blumchen K; Sher E; Spergel JM; Leickly FE; Zielen S; Wang J; Sanders GM; Wood RA; Cheema A; Bindslev-Jensen C; Leonard S; Kachru R; Johnston DT; Hampel FC; Kim EH; Anagnostou A; Pongracic JA; Ben-Shoshan M; Sharma HP; Stillerman A; Windom HH; Yang WH; Muraro A; Zubeldia JM; Sharma V; Dorsey MJ; Chong HJ; Ohayon J; Bird JA; Carr TF; Siri D; Fernández-Rivas M; Jeong DK; Fleischer DM; Lieberman JA; Dubois AEJ; Tsoumani M; Ciaccio CE; Portnoy JM; Mansfield LE; Fritz SB; Lanser BJ; Matz J; Oude Elberink HNG; Varshney P; Dilly SG; Adelman DC; Burks AW
    N Engl J Med; 2018 Nov; 379(21):1991-2001. PubMed ID: 30449234
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Peanut oral immunotherapy modifies IgE and IgG4 responses to major peanut allergens.
    Vickery BP; Lin J; Kulis M; Fu Z; Steele PH; Jones SM; Scurlock AM; Gimenez G; Bardina L; Sampson HA; Burks AW
    J Allergy Clin Immunol; 2013 Jan; 131(1):128-34.e1-3. PubMed ID: 23199605
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Peanut Oral Immunotherapy: State of the Art.
    Tang MLK; Lozinsky AC; Loke P
    Immunol Allergy Clin North Am; 2020 Feb; 40(1):97-110. PubMed ID: 31761124
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Early oral immunotherapy in peanut-allergic preschool children is safe and highly effective.
    Vickery BP; Berglund JP; Burk CM; Fine JP; Kim EH; Kim JI; Keet CA; Kulis M; Orgel KG; Guo R; Steele PH; Virkud YV; Ye P; Wright BL; Wood RA; Burks AW
    J Allergy Clin Immunol; 2017 Jan; 139(1):173-181.e8. PubMed ID: 27522159
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-Term Outcome of Peanut Oral Immunotherapy Facilitated Initially by Omalizumab.
    Yee CSK; Albuhairi S; Noh E; El-Khoury K; Rezaei S; Abdel-Gadir A; Umetsu DT; Burke-Roberts E; LeBovidge J; Schneider L; Rachid R
    J Allergy Clin Immunol Pract; 2019 Feb; 7(2):451-461.e7. PubMed ID: 30267889
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of oral immunotherapy with AR101 in European children with a peanut allergy (ARTEMIS): a multicentre, double-blind, randomised, placebo-controlled phase 3 trial.
    O'B Hourihane J; Beyer K; Abbas A; Fernández-Rivas M; Turner PJ; Blumchen K; Nilsson C; Ibáñez MD; Deschildre A; Muraro A; Sharma V; Erlewyn-Lajeunesse M; Zubeldia JM; De Blay F; Sauvage CD; Byrne A; Chapman J; Boralevi F; DunnGalvin A; O'Neill C; Norval D; Vereda A; Skeel B; Adelman DC; du Toit G
    Lancet Child Adolesc Health; 2020 Oct; 4(10):728-739. PubMed ID: 32702315
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Peanut oral immunotherapy in adolescents: study protocol for a randomized controlled trial.
    Michaud E; Evrard B; Pereira B; Rochette E; Bernard L; Rouzaire PO; Gourdon-Dubois N; Merlin E; Fauquert JL
    Trials; 2015 Apr; 16():197. PubMed ID: 25925398
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Peanut oral immunotherapy in a pediatric allergy clinic: Patient factors associated with clinical outcomes.
    Guarnieri KM; Slack IF; Gadoury-Lévesque V; Eapen AA; Andorf S; Lierl MB
    Ann Allergy Asthma Immunol; 2021 Aug; 127(2):214-222.e4. PubMed ID: 33839246
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Current Trend in Immunotherapy for Peanut Allergy.
    Joo Chan C; Richardo T; Lim RLH
    Int Rev Immunol; 2018; 37(6):279-290. PubMed ID: 30638084
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Severity and threshold of peanut reactivity during hospital-based open oral food challenges: An international multicenter survey.
    Arkwright PD; MacMahon J; Koplin J; Rajput S; Cross S; Fitzsimons R; Davidson N; Deshpande V; Rao N; Lumsden C; Lacy D; Allen KJ; Vance G; Mwenechanya J; Fox AT; Erlewyn-Lajeunesse M; Mistry H; Hourihane JO
    Pediatr Allergy Immunol; 2018 Nov; 29(7):754-761. PubMed ID: 30022517
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Monitoring Ara h 1, 2 and 3-sIgE and sIgG4 antibodies in peanut allergic children receiving oral rush immunotherapy.
    Nozawa A; Okamoto Y; Movérare R; Borres MP; Kurihara K
    Pediatr Allergy Immunol; 2014 Jun; 25(4):323-8. PubMed ID: 24953293
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of oral immunotherapy treatment in severe IgE mediated milk, peanut, and egg allergy in adults.
    Mäntylä J; Thomander T; Hakulinen A; Kukkonen K; Palosuo K; Voutilainen H; Pelkonen A; Kauppi P
    Immun Inflamm Dis; 2018 Jun; 6(2):307-311. PubMed ID: 29542268
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Peanut oral immunotherapy results in increased antigen-induced regulatory T-cell function and hypomethylation of forkhead box protein 3 (FOXP3).
    Syed A; Garcia MA; Lyu SC; Bucayu R; Kohli A; Ishida S; Berglund JP; Tsai M; Maecker H; O'Riordan G; Galli SJ; Nadeau KC
    J Allergy Clin Immunol; 2014 Feb; 133(2):500-10. PubMed ID: 24636474
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Blocking antibodies induced by peanut oral and sublingual immunotherapy suppress basophil activation and are associated with sustained unresponsiveness.
    Orgel K; Burk C; Smeekens J; Suber J; Hardy L; Guo R; Burks AW; Kulis M
    Clin Exp Allergy; 2019 Apr; 49(4):461-470. PubMed ID: 30383313
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy, Safety, and Quality of Life in a Multicenter, Randomized, Placebo-Controlled Trial of Low-Dose Peanut Oral Immunotherapy in Children with Peanut Allergy.
    Blumchen K; Trendelenburg V; Ahrens F; Gruebl A; Hamelmann E; Hansen G; Heinzmann A; Nemat K; Holzhauser T; Roeder M; Rosenfeld L; Hartmann O; Niggemann B; Beyer K
    J Allergy Clin Immunol Pract; 2019 Feb; 7(2):479-491.e10. PubMed ID: 30423449
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Open-label study of the efficacy, safety, and durability of peanut sublingual immunotherapy in peanut-allergic children.
    Kim EH; Keet CA; Virkud YV; Chin S; Ye P; Penumarti A; Smeekens J; Guo R; Yue X; Li Q; Kosorok MR; Kulis MD; Burks AW
    J Allergy Clin Immunol; 2023 Jun; 151(6):1558-1565.e6. PubMed ID: 36828080
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A pilot study of omalizumab to facilitate rapid oral desensitization in high-risk peanut-allergic patients.
    Schneider LC; Rachid R; LeBovidge J; Blood E; Mittal M; Umetsu DT
    J Allergy Clin Immunol; 2013 Dec; 132(6):1368-74. PubMed ID: 24176117
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sublingual immunotherapy for peanut allergy: Long-term follow-up of a randomized multicenter trial.
    Burks AW; Wood RA; Jones SM; Sicherer SH; Fleischer DM; Scurlock AM; Vickery BP; Liu AH; Henning AK; Lindblad R; Dawson P; Plaut M; Sampson HA;
    J Allergy Clin Immunol; 2015 May; 135(5):1240-8.e1-3. PubMed ID: 25656999
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.